Camurus Ab · OMXSTO:CAMX
Camurus Ab — Investor Presentation (January 2025)
30 slides from Camurus Ab's investor presentation, January 2025
Slide 1: Company presentation January 2025
Company presentation January 2025
Slide 2: Forward looking statements
2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-lo
Slide 3: Camurus snapshot
3 Camurus snapshot Rapidly growing commercial Unique FluidCrystal® stage company technology platform Leader in opioid dependence treatment Commercially validated with a broad with Buvidal® and Brixadi® weekly and range of applications monthly depots Advancing late-stage pipeline Strong operational a
Slide 4: Strategy focused on growth and innovation
4 Strategy focused on growth and innovation 1.1. Grow Buvidal/Brixadi sales and expand to new markets 2.2. Advance R&D pipeline to new approvals and launches 3.3. Diversify and grow through business development 4.4. Drive operational excellence and sustainable profitability Camurus' vision 2027 5x 4
Slide 5: Exiting 2024 with positive momentum
5 Exiting 2024 with positive momentum Strong commercial performance Advancing R&D pipeline Corporate development Global leadership in long-acting Positive results from 52-week Phase 3 Growing revenues and sustained treatment of opioid dependence ACROINNOVA 2 study in acromegaly profitability
Slide 6: Strong financial development
6 Strong financial development •Revenues •Profit before tax MSEK MSEK 2 000 600 549 1717 400 Raised 2024 Outlook* 1 500 Total revenues 200 SEK 1,810 – 1,880 million 1 000 956 73 +38 – 43% excl. one-time milestones 2023 0 601 Profit before tax 500 -112 336 -200 SEK 450 – 510 million -207 +214 – 256%
Slide 7: FluidCrystal extended-release technology
7 FluidCrystal® extended-release technology Easy and convenient administration Applicable across substance classes Rapid onset & long-acting release Compatible with prefilled syringes, autoinjector Controlled by composition, liquid crystal pens, and other advanced devices phase structure a
Slide 8: Broad and diversified product portfolio and pipeline
8 Broad and diversified product portfolio and pipeline Preclinical Phase 1 Phase 2 Phase 3 Registration Market Product on the market Buvidal® Opioid dependence Brixadi® Opioid use disorder (USA)1 Pipeline programs CAM2029 Acromegaly CAM2029 Gastroenteropancreatic neuroendocrine tumors CAM2029 Polycy
Slide 9: Buvidal – game changing opioid dependence treatment
9 Buvidal – game changing opioid dependence treatment Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over1 Demonstrated benefits to patients and s
Slide 10: Towards global leadership in long-acting opioid dependence treatment
10 Towards global leadership in long-acting opioid dependence treatment •Wide and growing access to Buvidal and Brixadi •Strong growth of Buvidal sales ‒ Available across four continents MSEK 1500 ‒ More than 56,000 in treatment with Buvidal in Europe 1299 and Australia end-Sep 2024 •Robust Buvidal
Slide 11: Accelerated growth of Brixadi in the US
11 Accelerated growth of Brixadi in the US •Brixadi launched in the US in September 2023 •Brixadi royalty by quarter ‒ Camurus’ licensee Braeburn responsible for US MSEK commercialization 60 58 ‒ Focused commercial organization of over 100 people 50 30% (39%CER) •Wide access to Brixadi for the treat
Slide 12: Buvidal/Brixadi – well differentiated
12 Buvidal/Brixadi – well differentiated •Convenient and flexible administration LAI features2 ‒ Weekly and monthly dosing ‒ Multiple dose strengths (four weekly, three monthly) Weekly dosing – – ‒ Choice of multiple injection sites Monthly dosing ‒ Thin needle and small dose volumes Multipl
Slide 13: Growing scientific evidence base
13 Growing scientific evidence base •Strong scientific support for Buvidal/Brixadi Recent key publications1-3 ‒ Documenting effectiveness in different treatment settings ‒ Positive health economical outcomes ‒ More than 160 scientific publications on Buvidal/Brixadi ‒ Ongoing clinical studies explor
Slide 14: Octreotide SC depot, CAM2029
14 Octreotide SC depot, CAM2029 CAM2029 is a long-acting octreotide in development for three serious rare disease indications • Acromegaly • Gastroenteropancreatic neuroendocrine tumors (GEP-NET) • Polycystic liver disease (PLD) •Designed for enhanced efficacy and patient convenience vs. current som
Slide 15: CAM2029 designed to address key limitations of current first-generation SRLs
15 CAM2029 designed to address key limitations of current first-generation SRLs Ready-to-use FluidCrystal® technology Rapid onset and long-acting octreotide release1 5-fold octreotide bioavailability vs Sandostatin LAR with potential for improved efficacy1-3 State-of-the-art, pre-filled autoinjector
Slide 16: CAM2029 provides high SRL exposure
16 CAM2029 provides high SRL exposure ~5x higher octreotide plasma exposure for CAM2029 vs. Sandostatin LAR ‒ CAM2029 octreotide plasma levels in the range of immediate release octreotide Steady state pharmacokinetic profiles 100 CAM2029 20mg q4w (PK model) Sandostatin IR 0.5mg TID (PK model) Sandos
Slide 17: CAM2029 clinical program overview
17 CAM2029 clinical program overview NDA filing MAA filing 5 completed 1 ACRO US ACRO EU Phase 1 and 2 clinical trials characterizing 2 Open label extension Est. NDA filing PK, PD and GEP-NET safety in healthy Fully recruited subjects and patients Open label extension Fully recruited Open label exte
Slide 18: Positive results from ACROINNOVA 1 – robust biochemical control
18 Positive results from ACROINNOVA 1 – CAM2029 provided robust biochemical control •ACROINNOVA 1 study design •Superiority achieved •CAM2029 improved ‒ 24-week, randomized, double blind, ‒ 77.2% vs. 37.5% patients with ‒ Treatment convenience placebo-controlled Phase 3 study IGF-1 ≤1 ULN with CAM20
Slide 19: Positive topline results from ACROINNOVA 2
19 Positive topline results from ACROINNOVA 2 •ACROINNOVA 2 study design •Improved acromegaly •ACROINNOVA 2 results ‒ 52-week, open-label safety study symptoms with CAM2029 ‒ Reinforcing long-term safety and with further extension effectiveness in ACROINNOVA 1 •Patient population 1 CAM2029 new patie
Slide 20: SORENTO assessing CAM2029 superiority in PFS vs SoC in patients with GEP-NET
20 SORENTO assessing CAM2029 superiority in PFS vs SoC in patients with GEP-NET •Randomized, active-controlled Phase 3 study •Primary endpoint ‒ Randomized, multi-center, open-label, active-controlled Phase ‒ Superiority in progression free survival, PFS, vs. standard 3 study of CAM2029 vs. long-act
Slide 21: Clinical Phase 2/3 study in PLD fully recruited
21 Clinical Phase 2/3 study in PLD fully recruited •POSITANO trial to assess efficacy and safety •Large unmet medical need in PLD ‒ 53-week randomized, placebo-controlled, three-arm study ‒ Severe quality-of-life implications for • Randomization of 71 patients completed in Q1 2024 patients with symp
Slide 22: CAM2029 progressing towards market with upcoming key milestones 2024/25
22 CAM2029 progressing towards market with upcoming key milestones 2024/25 Pivotal randomized placebo controlled Subcutaneous Octreotide Randomized Polycystic liver Safety and efficacy and long-term safety trials in acromegaly Efficacy in Neuroendocrine TumOrs TriAl with subcutaneous Octreotide Po
Slide 23: High market potential for CAM2029 – largest opportunity in GEP-NET
23 High market potential for CAM2029 – largest opportunity in GEP-NET Attractive specialty pharma opportunity ‒ Highly concentrated target audiences ‒ Differentiated product features ‒ Switch from established first-line treatments ‒ Blockbuster potential in GEP-NET alone • CAM2029 peak sales estimat
Slide 24: Once-monthly semaglutide entering clinical development
24 Once-monthly semaglutide entering clinical development •CAM2056 – once monthly FluidCrystal semaglutide ‒ Completed preclinical program met target profile for pharmacokinetics, pharmacodynamics (incl. weight management) and tolerability Clinical study under initiation ‒ Phase 1 study assessing ph
Slide 25: Significant near-term opportunities
25 Significant near-term opportunities Strengthening leadership in treatment of opioid dependence US and EU market approval decisions for CAM2029 in acromegaly US launch of Oclaiz in acromegaly Topline results from POSITANO and SORENTO studies of CAM2029 in GEP-NET and PLD Advancing early
Slide 26: Camurus AB contact details
Camurus AB │ Ideon Science Rydbergs torg Park, SE-223 4, SE-224 84 70 Lund, Lund, Sweden Sweden P +46 46 286 57 30 │ info@camurus.com │ camurus.com
Slide 27: Shareholders and analyst coverage
27 Shareholders and analyst coverage Shareholders as of 30 December 2024 Number of shares % of capital % of votes Sandberg Development AB 20,530,692 34.9 35.0 Fjärde AP-fonden 2,808,776 4.8 4.8 Analysts JP Morgan Chase Bank 2,341,984 4.0 4.0 Carnegie Swedbank Robur Fonder 2,181,347 3.7 3.7 Erik Hult
Slide 28: Experienced and committed management team
28 Experienced and committed management team Fredrik Tiberg, PhD Education: M.Sc. in Chem. Eng., Lund Institute of Technology, Jon Garay Alonso Education: Bachelor in Business Administration by President & CEO, CSO PhD and Assoc. Prof. Physical Chemistry, Lund University. Chief Financial Officer Uni
Slide 29: ACROINNOVA 1 Phase 3 RCT efficacy and safety trial
29 ACROINNOVA 1 Phase 3 RCT efficacy and safety trial • ACROINNOVA 1 trial design • Primary endpoint: • Secondary endpoints, e.g,: ‒ 24-week, randomized, double ‒ Proportion of patients with mean ‒ Time to loss of IGF-1 response blind, placebo-controlled trial IGF-1 ≤1xULN (week 22 and 24) ‒ IGF-1 a
Slide 30: ACROINNOVA 2 Phase 3 long-term safety and extension trial
30 ACROINNOVA 2 Phase 3 long-term safety and extension trial • ACROINNOVA 2 trial design • Primary endpoint: ‒ 52-week, open-label, long-term safety and extension trial ‒ Long-term safety and tolerability • Patient population • Secondary endpoints: ‒ New patients in trial; IGF-1<2xULN (n=81) ‒ Bioch